Phaseline

Targets › CYP2D6

CYP2D6 (Cytochrome P450 2D6): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 3 Phase 4; Infectious disease.

A cytochrome P450 monooxygenase involved in the metabolism of fatty acids, steroids and retinoids. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). (UniProt, P10635)

Open in Phaseline: the race on CYP2D6, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shoklo Malaria Research UnitTafenoquine
8-aminoquinoline; hypnozoitocidal agent targeting liver-stage malaria parasites
CYP2D6Phase 4Malaria–
Curtin UniversityTafenoquine
8-aminoquinoline with activity against hypnozoites and blood stages of Plasmodium vivax
CYP2D6Phase 4Pharmacokinetics of Tafenoquine–

Conditions

Malaria (2) Pharmacokinetics of Tafenoquine (1)

Modalities

small molecule (2)

Companies

Shoklo Malaria Research Unit (1) Curtin University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.